U.S. markets closed
  • S&P Futures

    3,826.00
    -2.00 (-0.05%)
     
  • Dow Futures

    31,354.00
    -17.00 (-0.05%)
     
  • Nasdaq Futures

    12,771.00
    -60.75 (-0.47%)
     
  • Russell 2000 Futures

    2,191.30
    -8.70 (-0.40%)
     
  • Crude Oil

    62.94
    -0.59 (-0.93%)
     
  • Gold

    1,768.00
    -7.40 (-0.42%)
     
  • Silver

    27.34
    -0.34 (-1.25%)
     
  • EUR/USD

    1.2164
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.3993
    -0.0019 (-0.14%)
     
  • USD/JPY

    106.2280
    -0.0020 (-0.00%)
     
  • BTC-USD

    46,944.95
    -3,537.01 (-7.01%)
     
  • CMC Crypto 200

    935.71
    -58.96 (-5.93%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,430.18
    -738.09 (-2.45%)
     

Recap: Deciphera Pharmaceuticals Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) were unchanged in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 16.03% year over year to ($1.10), which beat the estimate of ($1.15).

Revenue of $19,486,000 rose by 0.00% from the same period last year, which beat the estimate of $18,930,000.

Outlook

Deciphera Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Feb 09, 2021

View more earnings on DCPH

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/4mtugm7p

Price Action

Company's 52-week high was at $71.11

52-week low: $33.10

Price action over last quarter: down 19.99%

Company Profile

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations are functioned through the region of US.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.